Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
Get this delivered to your inbox, and more info about our products and services.
David Keller breaks down the technicals on this biotech giant.
Carter Worth breaks down the charts on this biotech stock.
Frank Cappelleri of CappThesis breaks down the bullish technical backdrop for this pharma-related stock.
The investment bank upgraded the pharma stock to overweight from equal weight.
The bank pointed to recent M&A success as a catalyst for the stock.
Carter Worth takes a look at the charts for mid-cap biotech Immunovant.
